Pharvaris (NASDAQ:PHVS) Reaches New 1-Year Low – What’s Next?

Pharvaris (NASDAQ:PHVS) hit a new 52-week low during trading on Wednesday . The company traded as low as $11.76 and last traded at $11.83, with a volume of 20599 shares changing hands. The stock had previously closed at $13.21.

Analysts Set New Price Targets

Separately, JMP Securities upped their price target on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Stock Down 3.3 %

The company has a market cap of $622.25 million, a PE ratio of -4.25 and a beta of -2.84. The business has a 50-day simple moving average of $15.66 and a 200-day simple moving average of $18.41.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.06. On average, research analysts forecast that Pharvaris will post -2.71 EPS for the current fiscal year.

Institutional Trading of Pharvaris

A number of hedge funds and other institutional investors have recently made changes to their positions in PHVS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Pharvaris by 30.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company’s stock valued at $1,222,000 after acquiring an additional 14,838 shares during the period. Woodline Partners LP acquired a new stake in shares of Pharvaris in the fourth quarter valued at $853,000. Soleus Capital Management L.P. boosted its stake in shares of Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock valued at $15,617,000 after buying an additional 216,483 shares during the period. Point72 Asset Management L.P. purchased a new position in Pharvaris in the fourth quarter worth approximately $152,000. Finally, Octagon Capital Advisors LP increased its position in shares of Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock valued at $14,914,000 after purchasing an additional 157,530 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.